82 related articles for article (PubMed ID: 10785267)
1. In vitro chemosensitivity testing in acute non lymphocytic leukemia using the bioluminescence ATP assay.
Möllgård L; Tidefelt U; Sundman-Engberg B; Löfgren C; Paul C
Leuk Res; 2000 May; 24(5):445-52. PubMed ID: 10785267
[TBL] [Abstract][Full Text] [Related]
2. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin.
Taub JW; Huang X; Matherly LH; Stout ML; Buck SA; Massey GV; Becton DL; Chang MN; Weinstein HJ; Ravindranath Y
Blood; 1999 Aug; 94(4):1393-400. PubMed ID: 10438727
[TBL] [Abstract][Full Text] [Related]
3. Breast cancer resistance protein expression and resistance to daunorubicin in blast cells from patients with acute myeloid leukaemia.
Sargent JM; Williamson CJ; Maliepaard M; Elgie AW; Scheper RJ; Taylor CG
Br J Haematol; 2001 Nov; 115(2):257-62. PubMed ID: 11703319
[TBL] [Abstract][Full Text] [Related]
4. In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia.
Klumper E; Ossenkoppele GJ; Pieters R; Huismans DR; Loonen AH; Rottier A; Westra G; Veerman AJ
Br J Haematol; 1996 Jun; 93(4):903-10. PubMed ID: 8703824
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia.
Legrand O; Simonin G; Beauchamp-Nicoud A; Zittoun R; Marie JP
Blood; 1999 Aug; 94(3):1046-56. PubMed ID: 10419897
[TBL] [Abstract][Full Text] [Related]
6. Comparison of a bioluminescence assay with differential staining cytotoxicity for cytostatic drug testing in vitro in human leukemic cells.
Rhedin AS; Tidefelt U; Jönsson K; Lundin A; Paul C
Leuk Res; 1993 Mar; 17(3):271-6. PubMed ID: 7680736
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia.
Uggla B; Tina E; Nahi H; Paul C; Höglund M; Sirsjö A; Tidefelt U
Int J Oncol; 2007 Jul; 31(1):153-60. PubMed ID: 17549416
[TBL] [Abstract][Full Text] [Related]
8. Assessment of the sensitivity of leukaemic cells to cytotoxic drugs by bioluminescence measurement of ATP in cultured cells.
Kuzmits R; Aiginger P; Müller MM; Steurer G; Linkesch W
Clin Sci (Lond); 1986 Jul; 71(1):81-8. PubMed ID: 3458552
[TBL] [Abstract][Full Text] [Related]
9. Leukaemia cell drug resistance and prognostic factors in AML.
Nørgaard JM; Olesen G; Kristensen JS; Pedersen B; Hokland P
Eur J Haematol; 1999 Oct; 63(4):219-24. PubMed ID: 10530409
[TBL] [Abstract][Full Text] [Related]
10. P-glycoprotein and multidrug resistance-associated protein, but not lung resistance protein, lower the intracellular daunorubicin accumulation in acute myeloid leukaemic cells.
Borg AG; Burgess R; Green LM; Scheper RJ; Liu Yin JA
Br J Haematol; 2000 Jan; 108(1):48-54. PubMed ID: 10651723
[TBL] [Abstract][Full Text] [Related]
11. In vitro chemosensitivity assessed with the MTT assay in childhood acute non-lymphoblastic leukemia.
Klumper E; Pieters R; Kaspers GJ; Huismans DR; Loonen AH; Rottier MM; van Wering ER; van der Does-van den Berg A; Hählen K; Creutzig U
Leukemia; 1995 Nov; 9(11):1864-9. PubMed ID: 7475276
[TBL] [Abstract][Full Text] [Related]
12. Topoisomerase IIalpha expression in acute myeloid leukaemia cells that survive after exposure to daunorubicin or ara-C.
Tina E; Prenkert M; Höglund M; Paul C; Tidefelt U
Oncol Rep; 2009 Dec; 22(6):1527-31. PubMed ID: 19885609
[TBL] [Abstract][Full Text] [Related]
13. Anthracycline drugs and MDR expression in human leukemia.
Pogliani EM; Belotti D; Rivolta GF; Maffè PF; Corneo G
Cytotechnology; 1996; 19(3):229-35. PubMed ID: 8862011
[TBL] [Abstract][Full Text] [Related]
14. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
[TBL] [Abstract][Full Text] [Related]
15. Cell cycle perturbations in acute myeloid leukemia samples following in vitro exposures to therapeutic agents.
Banker DE; Groudine M; Willman CL; Norwood T; Appelbaum FR
Leuk Res; 1998 Mar; 22(3):221-39. PubMed ID: 9619914
[TBL] [Abstract][Full Text] [Related]
16. Relation of blast cell survival and proliferation to chemotherapy resistance in AML.
Nørgaard JM; Langkjer ST; Palshof T; Clausen N; Pedersen B; Hokland P
Br J Haematol; 1996 Jun; 93(4):888-97. PubMed ID: 8703822
[TBL] [Abstract][Full Text] [Related]
17. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
[TBL] [Abstract][Full Text] [Related]
18. Expression of multidrug resistance (MDR) proteins and in vitro drug resistance in acute leukemias.
Fazlina N; Maha A; Jamal R; Zarina AL; Cheong SK; Hamidah H; Ainoon O; Zulkifli SZ; Hamidah NH
Hematology; 2007 Feb; 12(1):33-7. PubMed ID: 17364990
[TBL] [Abstract][Full Text] [Related]
19. In vitro drug resistance in acute myeloid and chronic B-lymphocytic leukaemic blasts and in normal blood and marrow populations.
Baines P; Limaye M; Hoy T; Padua RA; Whittaker J; al-Sabah A; Burnett A
Leuk Res; 1994 Sep; 18(9):683-91. PubMed ID: 7934144
[TBL] [Abstract][Full Text] [Related]
20. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
Grey M; Borg AG; Wood P; Burgess R; Fisher A; Yin JA
Leuk Res; 1997 Sep; 21(9):867-74. PubMed ID: 9393602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
